The analysis firm acknowledges LumiraDx for uniquely leveraging its expertise to satisfy prospects’ wants and capitalizing on new development alternatives
LONDON, Oct. 12, 2022 (GLOBE NEWSWIRE) — As we speak, LumiraDx (Nasdaq: LMDX), a next-generation level of care diagnostics firm, introduced it has been named by Frost & Sullivan because the 2022 Europe Know-how Innovation Chief for the microfluidics point-of-care (POC) diagnostics trade. The award acknowledges corporations which have launched one of the best underlying applied sciences for attaining product and buyer success whereas driving future enterprise worth.
LumiraDx was awarded for its POC Platform, which leverages lively microfluidic expertise to ship complete, correct, and real-time diagnoses throughout a rising take a look at menu to healthcare suppliers on the level of want.
The Frost and Sullivan analysis report evaluates corporations primarily based on a dedication to innovation, software variety, industrial success, buyer acquisition, and development potential. The report cited LumiraDx’s broad menu of exams and pattern sorts, superior expertise which simplifies, scales down, and integrates lab system rules into the low-cost POC platform and organizational construction which helps fast innovation and buyer acquisition.
Ojaswi Rana, Greatest Practices Analysis Analyst with Frost and Sullivan, said, “LumiraDx stands out from opponents primarily based on its dedication to innovation whereas additionally attaining industrial success. By deploying over 25,000 POC gadgets in additional than 100 nations to doctor places of work, pharmacies, acute and emergency care, and international well being techniques, we see not solely current industrial success but in addition immense development potential.”
David Walton, LumiraDx Chief Business Officer, said, “It’s an honor to be acknowledged by Frost and Sullivan as a Know-how Innovation Chief. LumiraDx’s next-generation level of care platform, together with a broad menu of exams, is driving a metamorphosis in neighborhood healthcare. Our superior lively microfluidic expertise is met with our mission to extend entry to testing and convey trusted outcomes nearer to the affected person. We’re happy with what we’ve achieved since our founding in 2014 and stay up for continued innovation.”
The total Frost and Sullivan analysis report could also be considered right here.
About LumiraDx
LumiraDx Restricted (Nasdaq: LMDX) is a next-generation level of care diagnostics firm that’s remodeling community-based healthcare. Its actively managed microfluidic expertise offers quick, excessive efficiency and accessible diagnostic options wherever the affected person is for practically any testing state of affairs, creating distinctive testing choices on the level of want.
The corporate provides a broad menu of lab comparable exams on a single transportable Platform, with greater than 30 assays in the marketplace and within the pipeline, masking infectious ailments, cardiovascular ailments, diabetes, and coagulation issues. The corporate additionally helps high-complexity laboratory testing in an accessible high-throughput format to leverage present molecular laboratory operations.
Based in 2014 and primarily based within the UK, LumiraDx’s diagnostic testing options are being deployed globally by governments and main healthcare establishments throughout laboratories, pressing care, doctor places of work, pharmacies, faculties, and workplaces to assist display screen, diagnose, and monitor wellness in addition to illness.
Extra data on LumiraDx is on the market at www.lumiradx.com.
About Frost & Sullivan
For six a long time, Frost & Sullivan has been world-renowned for its position in serving to buyers, company leaders, and governments navigate financial adjustments and establish disruptive applied sciences, Mega Tendencies, new enterprise fashions, and firms to motion, leading to a steady circulate of development alternatives to drive future success. Contact us: Begin the dialogue.
Contact: Colleen McMillenColleen.mcmillen@lumiradx.com
© OMX, supply GlobeNewswire – EU Press Releases
